https://proteasome-signals.com..../index.php/antiosteo
The HER2-low classification has brought about a re-examination of the established HER2 overexpression paradigm, underscoring the requirement for more rigorous HER2 testing methods to better encompass the intratumoral heterogeneity and spatial variability of HER2. It is uncertain whether the low HER2 marker will persist as a simple indicator of HER2-positive tumors susceptible to targeted thera
Tycka om
Kommentar
Dela med sig
